A Randomized controlled trial aiming to investigate whether ascorbic acid has a role in preventing vancomycin induced nephrotoxicity or not in critically ill patients.
Critically ill patients who have gram positive infection (MRSA) and need vancomycin will be assigned randomly into two groups. The first group will be given vancomycin intravenous only (15-20 mg/kg) every 8-12 hours , while the second group will take vancomycin intravenous (15-20 mg/kg) every 8-12 hours plus ascorbic acid 1 gram twice daily orally just before the vancomycin administration by half an hour. Patients will be monitored for one week where serum creatinine, BUN, urine output, trough level will be measured. Acute kidney injury will be determined according to RIFLE criteria.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
40
ascorbic acid is an antioxidant that is expected to prevent nephrotoxicty induced by Vancomycin.
Cairo university hospitals
Cairo, Egypt
RECRUITINGIncidence of nephrotoxicty
Incidence of nephrotoxicty will be described according to RIFLE criteria
Time frame: one week
28 days Mortality
Time frame: one month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.